FOR IMMEDIATE RELEASE
Fort Lauderdale, FL, April 20, 2018 -- Topstone Research, a full-service, contract research organization (CRO), has signed a new agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, Topstone will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Topstone research sites.
“We chose OmniComm because Topstone’s growing Data Management department is at a stage where we need to be better equipped to handle more complex trials, with a flexible and customizable EDC system,” said Muhammad Bilal, senior director-Clinical Data Management and Biostatistics at Topstone.
OmniComm was selected as one of Topstone preferred EDC systems based on TrialMaster’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to Topstone. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
“OmniComm continues to make significant progress in the CRO market due to the speed of setup and our comprehensive suite of very robust tools,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “We are thrilled that Topstone has selected TrialMaster to be deployed across a full spectrum of trial phases.”
About Topstone Research
Topstone Research is a specialty CRO with an unwavering commitment to quality and service flexibility. Topstone’s clinical professionals bring essential expertise to help biopharmaceutical organizations successfully solve today’s challenges in clinical research. In addition to offering a full selection of clinical trial management services, Topstone provides an unmatched and exceptional experience, from the first point of contact to final delivery. Please visit www.topstoneresearch.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems provides a role in enhancing patient lives by shortening time to market of essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]


Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Japan Earthquake Disrupts Auto and Chip Supply Chains
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 



